Form 4: Madrigal Pharmaceuticals SVP and CFO, Mardi Dier, Reports Stock and Option Awards
SEC Form 4
Mardi Dier, SVP and CFO of Madrigal Pharmaceuticals, reports the acquisition of restricted stock units and stock options.
Summary
- On March 5, 2025, Mardi Dier, SVP and CFO of Madrigal Pharmaceuticals, reported transactions involving the company's stock.
- Dier acquired 3,784 shares of common stock through a grant of restricted stock units.
- These restricted stock units vest in four equal installments on March 5 of 2026, 2027, 2028, and 2029, contingent upon continued service with the company.
- Dier also acquired options to purchase 6,374 shares of common stock at an exercise price of $347.28.
- These options vest 25% on March 5, 2026, and then 6.25% every three months thereafter, also contingent upon continued service.
- Following these transactions, Dier beneficially owns 10,698 shares of common stock and options for 6,374 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral-positive indicator.
Positives
- The grant of restricted stock units and stock options aligns the executive's interests with those of the shareholders.
- The vesting schedules incentivize continued service with the company.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock and options.
Industry Context
Stock and option awards are a common practice in the pharmaceutical industry to incentivize executives and align their interests with those of shareholders. The vesting schedules are designed to retain key personnel.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
- Vesting schedules, like the one described, are typical for retaining talent and aligning executive incentives with long-term company performance.
- Comparable companies such as Viking Therapeutics and Intercept Pharmaceuticals also utilize stock options and restricted stock units as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the stock and option awards as a positive sign, aligning management's interests with long-term company success.
- Employees may see this as a positive sign of company stability and commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of transaction: Grant of restricted stock units and stock options. |
| 03/05/2026 | First vesting date for 25% of the restricted stock units and stock options. |
| 03/05/2027 | Second vesting date for 25% of the restricted stock units. |
| 03/05/2028 | Third vesting date for 25% of the restricted stock units. |
| 03/05/2029 | Final vesting date for 25% of the restricted stock units. |
| 03/05/2035 | Expiration date for the stock options. |
| 03/07/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.